VasQ and A
The FDA has approved VasQ, a new device to reduce fistula failure, for a 2-year clinical trial with 129 patients. The device keeps fistulas from growing too large by providing an external support.
Read the full article » | Posted 08-17-2017
Related Articles
- Byonyks’ X1 APD Cycler Received FDA 510(k) Approval Last Summer Posted 02-17-2026
- FDA granted 510(k) approval to Outset for Next generation Tablo with Cybersecurity Posted 02-17-2026
- Drs. Monica Farcus and Jeffrey Perl Win the Mitchell Award for Health System Innovation Posted 01-16-2026
- Nephrodite Wins FDA Breakthrough Device Designation for “Holly” Posted 01-16-2026